Skip to main content

Month: March 2026

Xsolla SPAC 1 Announces the Separate Trading of its Class A Ordinary Shares and Warrants Commencing March 18, 2026

Sherman Oaks, CA, March 17, 2026 (GLOBE NEWSWIRE) — Xsolla SPAC 1, a newly organized special purpose acquisition company formed as a Cayman Islands exempted company (Nasdaq: XSLLU) (the “Company”), announced today that, commencing March 18, 2026, holders of the units sold in the Company’s initial public offering may elect to separately trade the Company’s Class A ordinary shares and warrants included in the units. No fractional warrants will be issued upon separation of the units and only whole warrants will trade. The Class A ordinary shares and warrants that are separated will trade on The Nasdaq Stock Market under the symbols “XSLL” and “XSLLW,” respectively. Those units not separated will continue to trade on The Nasdaq Stock Market under the symbol “XSLLU.” Holders of units will need to have their brokers contact Odyssey Transfer...

Continue reading

Kane Biotech Announces Publication in Frontiers in Antibiotics Highlighting Advancements in Treating Antibiotic Tolerant Biofilms

WINNIPEG, Manitoba, March 17, 2026 (GLOBE NEWSWIRE) — Kane Biotech Inc. (TSX-V:KNE) (“Kane Biotech” or “Kane”) announces that Frontiers in Antibiotics has published a peer-reviewed article authored by researchers from Kane Biotech and the University of Manitoba, detailing important scientific advancements in the fight against antibiotic-tolerant biofilms. Key messages of the article as it relates to Kane’s revyve wound gel include:revyve Antimicrobial Wound Gel demonstrated strong activity against antibiotic-tolerant biofilms, a major barrier in the treatment of chronic wounds. In both in vitro and ex vivo models, revyve eliminated mature Staphylococcus aureus and Pseudomonas aeruginosa biofilms, even after they had developed high levels of antibiotic tolerance. Following antibiotic pre-treatment, which generated highly antibiotic-tolerant...

Continue reading

Monte Rosa Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates

Positive interim Phase 1 data of NEK7-directed MGD MRT-8102 demonstrated profound CRP reductions in elevated CVD-risk subjects; readout of expanded part 3 CRP PoC trial (now called GFORCE-1) anticipated in H2 2026 Newly announced unblinded safety data from MRT-8102 SAD/MAD cohorts continue to support favorable safety/tolerability profile and wide therapeutic window Company plans to initiate multiple Phase 2 studies of MRT-8102, including in patients with elevated CVD-risk in H2 2026, in patients with gout flares in Q4 2026/Q1 2027, and in patients with moderate to severe hidradenitis suppurativa in H1 2027 Presented positive interim data from the Phase 1/2 clinical study of MRT-2359 in combination with enzalutamide showing 100% PSA response rate in metastatic castration-resistant prostate cancer (mCRPC) patients with AR mutations Phase...

Continue reading

Telesat reports results for the quarter and twelve months ended December 31, 2025

OTTAWA, Ontario, March 17, 2026 (GLOBE NEWSWIRE) — Telesat (Nasdaq and TSX: TSAT), one of the world’s largest and most innovative satellite operators, today announced its financial results for the three and twelve-month periods ended December 31, 2025. All amounts are in Canadian dollars and reported under IFRS® Accounting Standards unless otherwise noted. “Telesat made strong progress on multiple fronts in 2025,” commented Dan Goldberg, Telesat’s President and CEO. “The development of the Telesat Lightspeed constellation – the satellites, associated software, user terminals, and landing stations – continues to move forward at a rapid pace. We’re seeing strong interest in Telesat Lightspeed from customers across our target market segments, with demand from government users for defence and sovereignty requirements being particularly...

Continue reading

Vireo Growth Inc. Announces Fourth Quarter 2025 Results

Q4 GAAP revenue of $104.5 million increased 317.7% year-over-year, driven by recently closed M&A transactions On a pro forma basis, Q4 same store sales increased 22% year-over-year and wholesale revenue increased 55% year-over-year; excluding Minnesota, same store sales increased 11.3% year-over-year Announced the pending acquisitions of Eaze, Schwazze, and PharmaCann retail assets in Colorado, and MOU for the acquisition of Hawthorne, all of which are expected to close in the first half of 2026 Company closed Q4 with $122.5 million in cash; expects to remain acquisitive MINNEAPOLIS, March 17, 2026 (GLOBE NEWSWIRE) — Vireo Growth Inc. (“Vireo” or the “Company”) (CSE: VREO; OTCQX: VREOF), today reported financial results for its fourth fiscal quarter ended December 31, 2025. Key financial results are presented below in summary...

Continue reading

GDS Holdings Limited Reports Fourth Quarter and Full Year 2025 Results

SHANGHAI, China, March 17, 2026 (GLOBE NEWSWIRE) — GDS Holdings Limited (“GDS Holdings”, “GDS” or the “Company”) (NASDAQ: GDS; HKEX: 9698), a leading developer and operator of high-performance data centers in China, today announced its unaudited financial results for the fourth quarter and full year ended December 31, 2025. Fourth Quarter 2025 Financial HighlightsNet revenue increased by 8.6% year-over-year (“Y-o-Y”) to RMB2,921.7 million (US$417.8 million) in the fourth quarter of 2025 (4Q2024: RMB2,690.7 million). Net loss1 was RMB462.8 million (US$66.2 million) in the fourth quarter of 2025 (4Q2024: RMB173.4 million). Net loss margin was 15.8% in the fourth quarter of 2025 (4Q2024: 6.5%). Adjusted EBITDA (non-GAAP) increased by 5.2% Y-o-Y to RMB1,365.6 million (US$195.3 million) in the fourth quarter of 2025 (4Q2024: RMB1,297.7...

Continue reading

Guardian Capital Announces March 2026 Cash Distributions for Guardian Capital ETFs

TORONTO, March 17, 2026 (GLOBE NEWSWIRE) — Guardian Capital LP (the “Manager”) announces the following regular cash distributions for the period ending March 31, 2026, in respect of the ETF series of the Guardian Capital funds listed below (the “Guardian Capital ETFs”). In each case, the distribution will be paid on March 31, 2026 to unitholders of record on March 25, 2026. The ex-dividend date in each case is anticipated to be March 25, 2026.Guardian Capital ETFs Series of ETF Units DistributionFrequency TradingSymbol Exchange Distribution Amount(per ETF Unit)GuardBondsTM 2026 Investment Grade Bond Fund ETF Units Monthly GBFC Cboe Canada CAD$0.0248GuardBondsTM 2027 Investment Grade Bond Fund ETF Units Monthly GBFD Cboe Canada CAD$0.0264GuardBondsTM 2028 Investment Grade Bond Fund ETF Units Monthly GBFE Cboe Canada CAD$0.0312GuardBondsTM...

Continue reading

X4 Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

– Global 4WARD Phase 3 Chronic Neutropenia Trial On Track to Complete Enrollment in Q3 2026 – – Positive Opinion from European Medicines Agency Recommending Marketing Authorization of Mavorixafor for the Treatment of WHIM Syndrome in the European Union – – Balance Sheet Provides Cash Runway through 2028 – BOSTON, March 17, 2026 (GLOBE NEWSWIRE) — X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of people with rare hematology diseases, today reported financial results for the fourth quarter and year ended December 31, 2025 and provided a corporate update. “Our focus remains on our pivotal 4WARD trial in chronic neutropenia as we execute our strategy to deliver life-changing therapies to people living with rare blood diseases,” said Adam Craig, M.D., Ph.D., Executive Chairman...

Continue reading

Kraken Robotics Announces $24 Million in Defence Orders

ST. JOHN’S, Newfoundland and Labrador, March 17, 2026 (GLOBE NEWSWIRE) — Kraken Robotics Inc. (“Kraken” or the “Company”) (TSX-V: PNG, OTCQB: KRKNF) announces approximately $24 million in new orders to over 10 customers across five countries, including three new defence customers. The orders are for Kraken’s SeaPower batteries, KATFISH towed synthetic aperture sonar (SAS), and Kraken SAS. “SeaPower battery sales continue to be strong, with several new clients further diversifying our customer base in this area of the business. Manufacturing of our batteries in our new Nova Scotia facility is coming online in the next month, significantly expanding our production capacity” said Greg Reid, President and CEO of Kraken Robotics. “We are also pleased to share that we have sold a new KATFISH to the Polish Navy for their minehunting program...

Continue reading

AI Transformation at Risk: APIs Emerge as the Primary Attack Surface, Akamai Research Finds

Cybercriminals follow enterprise AI investment, exploiting APIs as the fastest path to scale, disruption, and profit CAMBRIDGE, Mass., March 17, 2026 (GLOBE NEWSWIRE) — Akamai (NASDAQ: AKAM) today released its 2026 Apps, APIs, and DDoS State of the Internet (SOTI) report, highlighting a decisive shift in the threat landscape. Attackers are now industrializing their methods and targeting the infrastructure that fuels business growth and AI transformation. As organizations accelerate AI adoption, APIs — long overlooked as a point of vulnerability — have become the primary attack surface. Akamai researchers have observed attacks evolve into coordinated campaigns that consistently blend API abuse, web application attacks, and Layer 7 DDoS activity into scalable, cost-efficient operations to disrupt availability and drive financial impact....

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.